Rice bran protein hydrolysates improve insulin resistance and decrease pro-inflammatory cytokine gene expression in rats fed a high carbohydrate-high fat diet

Nutrients

Volumn 7, Issue 8, 2015, Pages 6313-6329

  Boonloh, Kampeebhorn ^a   Kukongviriyapan, Veerapol ^a   Kongyingyoes, Bunkerd ^a   Kukongviriyapan, Upa ^a   Thawornchinsombut, Supawan ^a   Pannangpetch, Patchareewan ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Inflammatory cytokines; Insulin resistance; Metabolic syndrome; Rice bran protein hydrolysates (RBP)

Indexed keywords

ADIPONECTIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN HYDROLYSATE; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE; AUTACOID; CARBOHYDRATE DIET; FAT INTAKE; INSULIN;

ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CONTROLLED STUDY; FOOD INTAKE; FUNCTIONAL FOOD; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID HOMEOSTASIS; MALE; METABOLIC SYNDROME X; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN WEIGHT; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RICE BRAN; ADIPOSE TISSUE; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BLOOD; CHEMISTRY; DIET; DRUG EFFECTS; FAT INTAKE; FOOD GRAIN; GENETICS; INFLAMMATION; LIPOGENESIS; METABOLISM; ORYZA; SPRAGUE DAWLEY RAT;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CYTOKINES; DIET; DIETARY CARBOHYDRATES; DIETARY FATS; EDIBLE GRAIN; FUNCTIONAL FOOD; GENE EXPRESSION; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; LIPOGENESIS; MALE; METABOLIC SYNDROME X; ORYZA; PPAR GAMMA; PROTEIN HYDROLYSATES; RATS, SPRAGUE-DAWLEY;

EID: 84940856519     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7085292     Document Type: Article

References (42)

1. Miller, A.; Adeli, K. Dietary fructose and the metabolic syndrome. Curr. Opin. Gastroenterol. 2008, 24, 204-209. [CrossRef] [PubMed]
2. Ravussin, E.; Tataranni, P.A. Dietary fat and human obesity. J. Am. Diet. Assoc. 1997, 97, S42-S46. [CrossRef]
3. Panchal, S.K.; Poudyal, H.; Brown, L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J. Nutr. 2012, 142, 1026-1032. [CrossRef] [PubMed]
4. Hajer, G.R.; van Haeften, T.W.; Visseren, F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29, 2959-2971. [CrossRef] [PubMed]
5. Kim, C.S.; Lee, S.C.; Kim, Y.M.; Kim, B.S.; Choi, H.S.; Kawada, T.; Kwon, B.S.; Yu, R. Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice. Obesity (Silver Spring) 2008, 16, 1261-1269. [CrossRef] [PubMed]
6. Woods, S.C.; Seeley, R.J.; Rushing, P.A.; D'Alessio, D.; Tso, P. A controlled high-fat diet induces an obese syndrome in rats. J. Nutr. 2003, 133, 1081-1087. [PubMed]
7. Tripathy, D.; Mohanty, P.; Dhindsa, S.; Syed, T.; Ghanim, H.; Aljada, A.; Dandona, P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52, 2882-2887. [CrossRef] [PubMed]
8. Lionetti, L.; Mollica, M.P.; Lombardi, A.; Cavaliere, G.; Gifuni, G.; Barletta, A. From chronic overnutrition to insulin resistance: The role of fat-storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 2009, 19, 146-152. [CrossRef] [PubMed]
9. Iyer, A.; Fairlie, D.P.; Prins, J.B.; Hammock, B.D.; Brown, L. Inflammatory lipid mediators in adipocyte function and obesity. Nat. Rev. Endocrinol. 2010, 6, 71-82. [CrossRef] [PubMed]
10. Kershaw, E.E.; Flier, J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004, 89, 2548-2556. [CrossRef] [PubMed]
11. Park, E.J.; Lee, J.H.; Yu, G.Y.; He, G.; Ali, S.R.; Holzer, R.G.; Osterreicher, C.H.; Takahashi, H.; Karin, M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing il-6 and tnf expression. Cell 2010, 140, 197-208. [CrossRef] [PubMed]
12. Shi, H.; Tzameli, I.; Bjorbaek, C.; Flier, J.S. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J. Biol. Chem. 2004, 279, 34733-34740. [CrossRef] [PubMed]
13. Ruan, H.; Miles, P.D.; Ladd, C.M.; Ross, K.; Golub, T.R.; Olefsky, J.M.; Lodish, H.F. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: Implications for insulin resistance. Diabetes 2002, 51, 3176-3188. [CrossRef] [PubMed]
14. Matsuzawa, Y. Adiponectin: A key player in obesity related disorders. Curr. Pharm. Des. 2010, 16, 1896-1901. [CrossRef] [PubMed]
15. Patel, S.B.; Reams, G.P.; Spear, R.M.; Freeman, R.H.; Villarreal, D. Leptin: Linking obesity, the metabolic syndrome, and cardiovascular disease. Curr. Hypertens. Rep. 2008, 10, 131-137. [CrossRef] [PubMed]
16. Chandran, M.; Phillips, S.A.; Ciaraldi, T.; Henry, R.R. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003, 26, 2442-2450. [CrossRef] [PubMed]
17. Aldhahi, W.; Hamdy, O. Adipokines, inflammation, and the endothelium in diabetes. Curr. Diabetes Rep. 2003, 3, 293-298. [CrossRef]
18. Sonnenberg, G.E.; Krakower, G.R.; Kissebah, A.H. A novel pathway to the manifestations of metabolic syndrome. Obes. Res. 2004, 12, 180-186. [CrossRef] [PubMed]
19. Virtue, S.; Vidal-Puig, A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome-An allostatic perspective. Biochim. Biophys. Acta 2010, 1801, 338-349. [CrossRef] [PubMed]
20. Zhang, C.; Chen, X.; Zhu, R.M.; Zhang, Y.; Yu, T.; Wang, H.; Zhao, H.; Zhao, M.; Ji, Y.L.; Chen, Y.H.; et al. Endoplasmic reticulum stress is involved in hepatic srebp-1c activation and lipid accumulation in fructose-fed mice. Toxicol. Lett. 2012, 212, 229-240. [CrossRef] [PubMed]
21. Shimano, H.; Yahagi, N.; Amemiya-Kudo, M.; Hasty, A.H.; Osuga, J.; Tamura, Y.; Shionoiri, F.; Iizuka, Y.; Ohashi, K.; Harada, K.; et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 1999, 274, 35832-35839. [CrossRef] [PubMed]
22. Aragno, M.; Tomasinelli, C.E.; Vercellinatto, I.; Catalano, M.G.; Collino, M.; Fantozzi, R.; Danni, O.; Boccuzzi, G. Srebp-1c in nonalcoholic fatty liver disease induced by western-type high-fat diet plus fructose in rats. Free Radic. Biol. Med. 2009, 47, 1067-1074. [CrossRef] [PubMed]
23. Ide, T.; Shimano, H.; Yahagi, N.; Matsuzaka, T.; Nakakuki, M.; Yamamoto, T.; Nakagawa, Y.; Takahashi, A.; Suzuki, H.; Sone, H.; et al. Srebps suppress irs-2-mediated insulin signalling in the liver. Nat. Cell Biol. 2004, 6, 351-357. [CrossRef] [PubMed]
24. Boonloh, K.; Kukongviriyapan, U.; Pannangpetch, P.; Kongyingyoes, B.; Senggunprai, L.; Prawan, A.; Thawornchinsombut, S.; Kukongviriyapan, V. Rice bran protein hydrolysates prevented interleukin-6- and high glucose-induced insulin resistance in hepg2 cells. Food Funct. 2015, 6, 566-573. [CrossRef] [PubMed]
25. Justo, M.L.; Rodriguez-Rodriguez, R.; Claro, C.M.; Alvarez de Sotomayor, M.; Parrado, J.; Herrera, M.D.Water-soluble rice bran enzymatic extract attenuates dyslipidemia, hypertension and insulin resistance in obese zucker rats. Eur. J. Nutr. 2013, 52, 789-797. [CrossRef] [PubMed]
26. Kaup, R.M.; Khayyal, M.T.; Verspohl, E.J. Antidiabetic effects of a standardized egyptian rice bran extract. Phytother. Res. 2013, 27, 264-271. [CrossRef] [PubMed]
27. Kozuka, C.; Yabiku, K.; Takayama, C.; Matsushita, M.; Shimabukuro, M. Natural food science based novel approach toward prevention and treatment of obesity and type 2 diabetes: Recent studies on brown rice and gamma-oryzanol. Obes. Res. Clin. Pract. 2013, 7, e165-e172. [CrossRef] [PubMed]
28. Fabian, C.; Ju, Y.H. A review on rice bran protein: Its properties and extraction methods. Crit. Rev. Food Sci. Nutr. 2011, 51, 816-827. [CrossRef] [PubMed]
29. Thawornchinsombut, S.; Kokkaew, H. Production of rice bran protein hydrolysates with anti-hypertensive property. Thailand Mini Patent 4844, 2008.
30. Panchal, S.K.; Poudyal, H.; Iyer, A.; Nazer, R.; Alam, M.A.; Diwan, V.; Kauter, K.; Sernia, C.; Campbell, F.; Ward, L.; et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J. Cardiovasc. Pharmacol. 2011, 57, 611-624. [CrossRef] [PubMed]
31. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412-419. [CrossRef] [PubMed]
32. Samatiwat, P.; Prawan, A.; Senggunprai, L.; Kukongviriyapan, V. Repression of nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn Schmiedebergs Arch. Pharmacol. 2015, 388, 601-612. [CrossRef] [PubMed]
33. Mlinar, B.; Marc, J.; Janez, A.; Pfeifer, M. Molecular mechanisms of insulin resistance and associated diseases. Clin. Chim. Acta 2007, 375, 20-35. [CrossRef] [PubMed]
34. Knight, Z.A.; Hannan, K.S.; Greenberg, M.L.; Friedman, J.M. Hyperleptinemia is required for the development of leptin resistance. PLoS ONE 2010, 5, e11376. [CrossRef] [PubMed]
35. Okamoto, Y.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Libby, P. Adiponectin: A key adipocytokine in metabolic syndrome. Clin. Sci. (Lond.) 2006, 110, 267-278. [PubMed]
36. Bastard, J.P.; Maachi, M.; Lagathu, C.; Kim, M.J.; Caron, M.; Vidal, H.; Capeau, J.; Feve, B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17, 4-12. [PubMed]
37. Raucci, R.; Rusolo, F.; Sharma, A.; Colonna, G.; Castello, G.; Costantini, S. Functional and structural features of adipokine family. Cytokine 2013, 61, 1-14. [CrossRef] [PubMed]
38. Tsuchida, A.; Yamauchi, T.; Takekawa, S.; Hada, Y.; Ito, Y.; Maki, T.; Kadowaki, T. Peroxisome proliferator-activated receptor (ppar)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison of activation of pparalpha, ppargamma, and their combination. Diabetes 2005, 54, 3358-3370. [CrossRef] [PubMed]
39. Viana Abranches, M.; Esteves de Oliveira, F.C.; Bressan, J. Peroxisome proliferator-activated receptor: Effects on nutritional homeostasis, obesity and diabetes mellitus. Nutr. Hosp. 2011, 26, 271-279. [PubMed]
40. Maeda, N.; Takahashi, M.; Funahashi, T.; Kihara, S.; Nishizawa, H.; Kishida, K.; Nagaretani, H.; Matsuda, M.; Komuro, R.; Ouchi, N.; et al. Ppargamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50, 2094-2099. [CrossRef] [PubMed]
41. Kim, H.J.; Kim, S.K.; Shim, W.S.; Lee, J.H.; Hur, K.Y.; Kang, E.S.; Ahn, C.W.; Lim, S.K.; Lee, H.C.; Cha, B.S. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2008, 81, 42-49. [CrossRef] [PubMed]
42. Pereira, R.I.; Leitner, J.W.; Erickson, C.; Draznin, B. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase. Life Sci. 2008, 83, 638-643. [CrossRef] [PubMed]